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Preface
Hedgehog (Hh) signaling regulates numerous events in embryonic development and
adult tissue maintenance. Damage to essential core components of the Hh pathway
often results in congenital birth defects whereas an aberrant activated Hh pathway
leads to cancer.1 The signaling begins with the binding of Hh protein ligand to
its membrane receptor PTCH, which represses the activity of Smoothened (Smo).
Smo in turn promotes the expression of GLI (Glioma-associated oncogene) family
of transcription factors, leading to tumor development (Figure 1).2
Figure 1: Hh Signaling pathway (A) In the absence of Hh signaling, Smo localizes
mainly to the cell membrane (B) In the presence of Hh, repression of Smo by Ptch is
relieved. Smo repression will activate GLI proteins, leading to oncogene expression.
GLIs, which are zinc-finger transcription factors, are known to regulate several genes,
including cell cycle control-related genes and Hh/GLI signaling.3 There are 3 GLI
genes in vertebrate cells; GLI1, GLI2 and GLI3. Evidence suggests that GLI1 and
viii
GLI2 represent the main activators of Hh target genes, while GLI3 acts mainly as
repressor.4
Unlike GLI2 and GLI3, which are considered latent transcriptional regulators, GLI1
represents a direct transcriptional Hh-target gene. This transcriptional effector is
closely associated with tumor formation by direct association with a specific binding
site (5’-GACCACCCA-3’) in the promoter region of the target genes.5
The Hh/GLI signaling is constitutively activated in several types of human tumors
such as basal cell carcinoma and medullablastoma due to mutations in Ptch or
Smo. This mutation will activate GLI1-mediated transcription hence cause tumor
formation and progression.6 In Hh signaling, GLI1 is considered to participate in
the final step of the activation.
The regulation of GLI1 in mediating oncogenic Hh signaling is poorly known. Some
reports describe that activated mutations of Smo induce the nuclear translocation of
transcriptional GLI factors.7,8 The use of small molecule inhibitors of Smo showed
potentially limited efficacy. These inhibitors only treat tumors where pathway ac-
tivation has occurred upstream or at the level of Smo, yet cancer with other down-
stream components is unresponsive to Smo inhibitors.9
Although there is a well-documented role for the Hedghog signaling pathway in
cancer, there are relatively few synthetics and naturally occurring Hh signaling
antagonists available that target GLI1 (GANTs).10 Other sites that were mainly
targeted are Smo protein (cyclopamine,11,12 SANTs,13 and CUR6141414) and Hh
ligand (robotnikinin15) (Figure 2). Three synthetics are now entering clinical phase-
1 studies (HhAntag691, GDC-0449, and BMS-833923).16
Given the essential role of Hh signaling pathway in the development of cancer as
well as the prominent role of natural products in drug discovery, there remains an
urgent need to find more potent Hh signaling inhibitors from natural resources.
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Figure 2: Components of the Hh signaling pathway and molecular
sites targeted by Hh pathway inhibitors.
To identify naturally occuring inhibitors of the Hh/GLI signaling pathway, Pro-
fessor Masami ISHIBASHI and his group reported the successful construction of a
cell-based screening assay system17 and have recently isolated several naturally oc-
curring Hh/GLI inhibitors.18−23 This thesis presented the search for small molecule
inhibitors from natural resources interfering with GLI function.
To screen natural product libraries, a previous constructed cell screen of expressed
exogenous GLI1 in HaCaT under tetracycline control (T-REx system) was used.17
To identify the cell viability of compounds, a fluorometric microculture cytotoxicity
(FMCA) method24 was performed. A screening program has identified Acacia pen-
nata, Excoecaria agallocha, Vallaris glabra, Ocimum gratissimum and Piper chaba
as hit plants. These plants were further isolated, guided by Hh/GLI signaling in-
hibition. The inhibition of GLI-mediated transcriptional activity, cytotoxicity, and
the effect of selected inhibitors on protein expression were further examined.
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Chapter 1
Assay Protocol
1.1 GLI Transcriptional Activity
Firefly luciferase, a 61 kDa monomeric protein, functions as a genetic reporter. The
luciferase system is considered as a sensitive reporter assay for gene expression.
Figure 1.1: Luminescence reactions catalyzed by firefly
Principally, luminescence is achieved through oxidation of beetle luciferin in a reac-
tion that requires ATP, Mg2+ and O2 (Figure 1.1). The oxidation occurs through
a luciferyl-AMP intermediate that results in a flash of light. The flash rapidly
decays after the substrate and enzyme are mixed.
1
GLI transcriptional activity was calculated from the ratio of the reporter luciferase
activity of sample-treated cells/non-treated cells ;
1.2 Cell Viability
Cell viability of sample was measured by Fluorometric Microculture Cytotoxicity
Assay1 (FMCA) method using Fluorescein Diacetate (FDA) as a dye. FDA is a
nonfluorescent compound which is converted to fluorescence intensity. The assay
is based on hydrolysis of the probe, FDA by esterases in cells with intact plasma
membranes (Figure 1.2). The conversion is directly proportional to the number of
viable cells which is calculated as follows:
Figure 1.2: The conversion by viable cells of fluorescein diacetate to fluorescent
fluorescein
2
Figure 1.3: Constructed Screening System
1.3 Compound Screen
HaCaT cells were stably co-transfected with plasmid pcDNA3.1-GLI1, which pro-
duced exogenous GLI1 proteins, together with the reporter plasmid pcDNA3.1-GLI-
luc, which produced luciferase by GLI1-mediated transactivation and pcDNA6/TR.
In this compound screening, tetracycline, which introduces exogenous GLI1 over-
expression, was removed when compounds were added to HaCaT-GLI1-Luc cells
(Tet-On system) (Figure 1.3).
Cells (HaCaT-GLI1-Luc) were seeded in a 96-well white plate at 2 x 104 per well.
After 12 h incubation at 37 0C, tetracycline (Tc) 1 µg/mL was added and cells
were incubated for another 12 h. Compounds were added at various concentrations
and subsequently, luciferase activity was measured on a microplate luminometer
(Thermo) using the Bright-GloTM Luciferase Assay System (Promega) according
to the manufacturer’s protocol. Simultaneously, the cell viability of the compound-
treated cells was measured by FMCA using a fluorescence plate reader (Thermo)
3
Figure 1.4: Hh/GLI-Signaling Inhibitory assay
(Figure 1.4).
As depicted in Figure 1.5, light orange bar represents luciferase activity and dark
orange represents the viability of sample. If the percentage of luciferase activity is
low but the percentage of cell viability high, compound is considered to positively
inhibit Hh/GLI signaling.
Figure 1.5: Hh/GLI-Signaling Inhibitory activity of compounds
1.4 Cytotoxicity Test
PANC1, C3H10T1/2 (RIKEN BRC) or DU145 (Cell Resource Center for Biomedical
Research Institute of Development, Aging and Cancer, Tohoku University) were
4
Figure 1.6: Hh/GLI-Signaling inhibition of some medicinal plant extracts col-
lected from Thailand (KKP0019: Nauclea orientalis) and Bangladesh (KKB0010:
Sida rhombifolia, KKB0017: Ficus racemosus, KKB0040: Rhizophora mucronata,
KKB0051: Alombus meruensis, KKB0114: Boerhavia diffusa).
seeded in black 96-well plates at 1 x 104 cells per well. After incubation at 37
0C for 24 h, medium was replaced by compounds at different concentrations. Cell
proliferation was determined by FMCA, and IC50 values were determined. Assays
were performed in triplicate.
1.5 Screening of Plant Extract Library
Medicinal plants, collected from Thailand (KKP) and Bangladesh (KKB), were
screened for Hh/GLI-Signaling Inhibition. About 73 Bangladesh plants (KKB001-
KKB0057 and KKB101-KKB117) were screened and the inhibitory activity charts
were attached at Appendix I. Activity of some selected extracts is shown in Figure
1.6.
5
Activity of KKP0019, KKP0023, and KKP0252, showed in Figure 1.6, were screened
by Mr. Chikashi Tateno in 2009.
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Chapter 2
Separation of Acacia pennata
The leaves of Acacia pennata (Figure 2.1), locally in Thailand known as cha-om, are
used in indigenous systems of medicine. Although several compounds were reported
from Acacia pennata including alkaloids, saponins, polysachharides, terpenoids, con-
densed tannins and flavonoids1, relatively little is known about the pharmacological
effect of this plant.
2.1 Extraction and Isolation
Leaves (10.0 g) of Acacia pennata were extracted with MeOH. The MeOH extract
was partitioned with hexane (200 mL x 3), EtOAc (200 mL x 3), and BuOH (200
mLx 3). The EtOAc-soluble fraction (1.9 g) was subjected to silica gel column
chromatography (40 x 260 mm), and eluted successively with a gradient mixture
of hexane-EtOAc-MeOH (10:2:1 to 2:2:1) to yield 6 fractions (2A to 2G). Fraction
2D (390.3 mg) was underwent ODS flash column chromatography (12 x 245 mm)
to give fractions 3A-3J. Active fraction 3E (131.2 mg) was further separated by
PSQ-100B silica gel column chromatography (30.3 mg), followed by passage over
Sephadex LH-20 (10 x 150 mm), using methanol 100%, to afford compounds 1 (13.8
7
Figure 2.1: Acacia pennata
mg), 2 (3.0 mg), and 3 (3.7 mg). Fraction 1F (161 mg), separated from the hexane
extract (0.98 g), was chromatographed over 60 N silica gel (20 x 450 mm), using
hexane-CHCl3-EtOAc (from 16:1:1 to 0:2:1), to yield compound 4 (8.1 mg) and
compound 5 (2.0 mg).
2.2 Structure Elucidation
Bioassay-guided separation of Acacia pennata (Figure 2.2) led to the isolation of 5
known compounds from hexane and EtOAc extracts. Compounds 1-5were identified
by comparing their spectroscopic data to literature values (Figure 2.3).
Taepeenin D (1)2
1H and 13C NMR data, see Table 2-1, EIMS m/z [M + Na]+ 407
8
Figure 2.2: Isolation Scheme of Acacia pennata
Drimenin (2)3
1H and 13C NMR data, see Table 2-2, FAB MS m/z [M + H]+ 207
Labdanolic acid (3)4
1H and 13C NMR data, see Table 2-3, EIMS m/z [M + Na]+ 347, [α]23D -6.07 (c 0.35,
MeOH)
8,15-labdanediol (4)5
1H and 13C NMR data, see Table 2-3, FAB MS m/z [M + K]+ 349, [α]22D -5.37 (c
0.61, CHCl3)
9
Quercetin-3-β-D-glucopyranosyl-4-O-β-D-glucopyranoside (5)6
1H and 13C NMR data, see Table 2-4, FAB MS m/z [M + Na]+ 649
Figure 2.3: Structures of 1-5
2.3 Activity Assay
The isolated compounds 1-5 were evaluated for their GLI-mediated transcriptional
activity. Compounds 1, 2, and 5 inhibited Hh/GLI-mediated transcriptional activity
with IC50 values of 1.6, 13.5, and 10.5 µM, respectively, whereas compounds 3 and
4 were inactive (Figure 2.4 A, Table 2-5).
As for cytotoxicity assays, a panel of cells was included with increased Hh sig-
naling levels (PANC1 and DU145) and without reliance on Hh ligand for survival
(C3H10T1/2). The results revealed that compounds 1, 2, and 5 were cytotoxic
against PANC1 cells (IC50 values of 3.2, 15.1, and 26.6 µM, respectively) and DU145
cells (IC50 values of 3.4, 23.2, and 30.0 µM, respectively) but did not affect normal
cell lines (Figure 2.4 B, Table 2-5).
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Figure 2.4: (A) Inhibition of GLI1-mediated transcriptional activity (solid columns)
and cell viability (solid curves) of compounds 1, 2, and 5. HaCaT-GLI1-Luc cells
were seeded onto a 96-well plate (2 x 105 cells per well) then treated with compounds
after 12 h tetracycline addition. Cell viability and luciferase activity were determined
at the same time. The assays were performed at 0.05 % DMSO (n = 3). Error bars
represent s.d. (B) Cytotoxicity of compounds 1, 2, and 5 against PANC1, DU145,
and C3H10T1/2 cells. The assays were performed 0.05 % DMSO (n = 3). Error
bars represent s.d.
GLI1 transcriptional factors are known to regulate expression of multiple targets
including PTCH7 and BCL-2.8 Both proteins were over-expressed in HaCaT-GLI1-
Luc cells and PANC1. Although compounds 1, 2, and 5 differently interfered with
PTCH and BCL-2 proteins, western blot analysis confirmed that each compound re-
duced the expression of both proteins in a concentration-dependent fashion (Figure
2-5). It is also important to note that the GLI1 protein level in HaCaT cells de-
creased for compound 1 but not for compounds 2 and 5. In this assay, tetracycline,
which introduces exogenous GLI1 over-expression, was removed when compounds
11
Figure 2.5: Inhibition of GLI-related protein (PTCH and BCL2) levels by com-
pounds 1, 2, and 5. (A) Treatment of 1, 2, and 5 on GLI1-overexpressing HaCaT
cells. (B) Treatment of 1, 2, and 5 on PANC1 cells.
were added to HaCaT-GLI1-Luc cells. Therefore, compound 1 might accelerate
GLI1 protein degradation in HaCaT-GLI1-Luc cells. These results thus indicated
that different structures had different target molecules.
Furthermore, the inhibition of Ptch mRNA expression by taepeenin D (1) in PANC1
was examined using real time-PCR analysis. Cyclopamine, a steroidal alkaloid that
inhibits the Hh response,9 was included as a positive control. The antagonism of Smo
was reported previously as a target of cyclopamine action.10,11 As depicted in Figure
2.6, treatment of 1 at 2 and 4 µM reduced the mRNA expression of Ptch compared to
a negative control. Similar trend of inhibition was apparent on the mRNA expression
of cyclopamine-treated cancer cells. A report by Chatel et al. highlighted the fact
that treatment of cyclopamine (10 µM) modulated Ptch expression in PANC1 due
to the inhibition of Gli1 mRNA level,12 thereby suggesting that taepeenin D (1) is
also an effective inhibitor of the Hh signaling pathway.
In conclusion, three constituents of Acacia pennata leaves were found to inhibit Hh
12
Figure 2.6: Inhibition of GLI1-mediated mRNA expression of Ptch by compound 1
in PANC1 cells. GAPDH was used as an internal control. The assays were performed
at 0.05 % DMSO (n = 3). Error bars represent s.d.
signaling. This inhibition was caused by downregulated Ptch mRNA expression
along with decreased protein level of PTCH and BCL-2 in HaCaT cells expressing
exogenous GLI1 and PANC1 cells.
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Chapter 3
Separation of Excoecaria
agallocha
Excoecaria agallocha Linn. (Euphorbiaceae) (Figure 3.1) is a mangrove tree that
is widely distributed throughout the forests and swamps of the Sundarbans, in
coastal areas of Bangladesh and in wetland along the coastline of China.1 This
plant, known locally as Gewa, has been traditionally used to treat skin irritation and
potentially shows anti-tumor-promoting2 and anti-HIV activities.3 Previous phyto-
chemical studies on Excoecaria agallocha revealed the presence of diterpenoids,2,3
triterpenoids,1 and flavonoids.4
3.1 Extraction and Isolation
The MeOH extract (20.5 g) was subjected to Diaon HP-20 column chromatography
(50 x 250 mm) using mixtures of MeOH/acetone to yield MeOH-soluble fractions.
This MeOH-soluble part (4.1 g) was partitioned with H2O (200 mL) between hexane
(200 mL x 3), and the aqueous phase was further extracted with EtOAc (200 mL
x 3) and BuOH (200 mL x 3) to afford hexane extract (537.2 mg), EtOAc extract
17
Figure 3.1: Excoecaria agallocha
(2.62 g), BuOH extract (645.0 mg) and H2O extract (252.5 g).
BuOH extract (645.0 mg) was chromatographed on a silica gel 60 N column (20 x
350 mm) using the increasing polarity of the MeOH : H2O solvent system to afford
fractions 3A-3F. Compounds 6 (15 mg), 11 (2.7 mg) and 12 (7.4 mg) were isolated
from fraction 3D (69.2 mg), 3E (82.7 mg), and 3F (185.5 mg) respectively after
silica gel 60 N column chromatography (16 x 400 mm) using CHCl3 : MeOH as the
solvent system.
The EtOAc-soluble fraction (2.62 g) was subjected to ODS flash column chromatog-
raphy (30 x 280 mm), and eluted successively with a gradient mixture of MeOH:
H2O (20 : 80 to 0 : 100) to yield 9 fractions (2A to 2I). Fraction 2C (430.6 mg) was
subjected to Sephadex LH-20 column chromatography using MeOH as the eluent
to obtain compound 8 (19.3 mg). Another active fraction from the EtOAc extract
(fraction 2D, 234.4 mg) was underwent silica gel 60N column chromatography (25
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Figure 3.2: Isolation Scheme of Excoecaria agallocha
x 580 mm) and was eluted with increasing MeOH (30-100 %) in H2O to give 11
fractions (4A-4K). Fractions 4F and 4K were determined as compounds 9 (29.7 mg)
and 13 (4.0 mg) respectively. From 4J (11.7 mg), compound 7 (2.5 mg) were ob-
tained after preparative HPLC (inertsil ODS-3, 10 x 250 mm; MeOH : H2O (6 : 4);
flow rate 1.5 mL min-1; RI and UV detection at 254 nm). Furthermore, fraction 2 E
(312.1 mg) of the EtOAc extract was underwent preparative HPLC (inertsil ODS-5,
6.0 x 250 mm; MeOH : H2O (7 : 3); flow rate 2.0 mL min
−1; RI and UV detection
at 254 nm) to afford compound 10 (31.9 mg).
3.2 Structure Elucidation
Separation of Excoecaria agallocha guided by Hedgehog/GLI signaling inhibition
led to the isolation of 2 new compounds (6 and 7) along with 6 known flavonoid
19
Figure 3.3: Structure of Compound 6
glycosides (8-13) (Figure 3.2).
3.2.1 New Compounds
Compound 6 (Figure 3.3) was obtained as a yellow powder and had a molecu-
lar weight at m/z 485.1162 ([M+Na]+, -2.1 mmu), corresponding to the molecular
formula of C22H22O11 in the HR-FABMS. The IR absorption bands suggested the
presence of hydroxyl (3317 cm-1) (br) and carbonyl (1680 cm-1) groups. The UV
absorption maxima were at UV (MeOH) λ max 261 nm (log  3.8) and 355 nm (log
 3.0). Acid hydrolysis of compound 6 gave quercetin and acofriose (3-O-methyl
rhamnose). Acofriose was determined as having an L-form by comparison of its
specific rotation [α]22D +35 (c 0.1, MeOH) with those reported in the literature [α]
22
D
+39.5 The carbon signals at δC 177.7 (C-4), 148.4 (C-3’) and 145.2 (C-4’) were in
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Figure 3.4: Key 1H-1H COSY and HMBC correlations observed for 6
agreement with the quercetin skeleton bearing a carbonyl and two hydroxyl groups.
In addition, four signals of OH hydrogens were observed at δH 12.63 (1H, s), 10.88
(1H, s), 9.71 (1H, s), and 9.34 (1H, s). The location of the sugar part, according
to HMBC analysis (Figure 3.4), was shown to attach to the C-3 of aglycone. The
small coupling constant (1.6 Hz) of the anomeric proton (δH 5.24) indicated its α
configuration.6
Compound 7 (Figure 3.5) was isolated as a yellow amorphous solid and gave the
molecular formula C27H30O15, as deduced from HR-FABMS m/z 617.1584 (calcd for
C27H30O15Na, 617.1558). The proton signals showed two aromatic doublets at δH
6.20 and 6.39, and an ABX system at δH 7.66 (J = 2 Hz), 6.84 (J = 8 Hz), and 7.56
(J = 2 Hz and 8 Hz), confirming that the aglycone was quercetin. The 13C NMR
spectrum of 7 showed 27 resonances, including one methoxy group (δC 48.5) attached
to one of the sugar moieties. Comparison of NMR spectral data of 7 differed from
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Figure 3.5: Structure of compound 7, key 1H-1H COSY and HMBC correlations
observed for 7
22
23
6 in the sugar chain. Further HMBC analysis (Fig. 2) indicated the connections of
sugar units between δH 5.46 (H-1”) and δC 133.4 (C-3), and between δH 3.63 (H-5”)
and δC 101.7 (C-1”’). Acid hydrolysis and HPLC isolation gave quercetin, D-apiose
and L-acofriose. The orientation of the anomeric proton of the first sugar (D-apiose,
δ 5.46) was deduced as β since the coupling constant was smaller (J = 3.3 Hz)7 than
that of α (J = 4.5 Hz).8 Furthermore, the small coupling constant observed for the
anomeric proton of the second sugar (L-acofriose, δH 5.37, J = 2.0 Hz) suggested its
α configuration.6 The D-form of the first sugar connected to aglycone was confirmed
by comparing its specific rotation [α]21D +6.1 (c 0.03, H2O) with the reported values
of an authentic sample, [α]22D +5.2 (c 1.1, H2O).
9 The downfield location of the C-3”’
absorption of the second sugar showed the presence of a methoxy group at C-3”’.
The sugar was identified as 3-O-methyl-rhamnose and was confirmed as having an
L-form by the same method as compound 6.
3.2.2 Known Compounds
Quercitrin (8)18
1H and 13C NMR data, see Table 3-3, FAB MS m/z [M + Na]+ 471
Afzelin (9)19
1H and 13C NMR data, see Table 3-3, FAB MS m/z [M + Na]+ 455
Kaempferol-3-O-(2-O-acetyl-α-L-rhamnopyranoside (10)20
1H and 13C NMR data, see Table 3-3, FAB MSm/z [M + H]+ 475
Rutin (11)21
1H and 13C NMR data, see Table 3-4, FAB MS m/z [M + Na]+ 633
Kaempferide 3-O-α-L-rhamnopyranoside (12)22
24
1H and 13C NMR data, see Table 3-4, FAB MS m/z [M + K]+ 485
Kaempferol 3-O-α-L-arabinofuranoside (13)23
1H and 13C NMR data, see Table 3-4, FAB MS m/z [M + Na]+ 441
3.3 Acivity Assay
Hh/GLI1 inhibitory effects of all isolated compounds (6-13) were further evaluated.
Compounds 6, 7 and 13 inhibited Hh/GLI-mediated transcriptional activity with
IC50 values of 0.5, 19.1 and 2.0 µM, respectively, whereas compounds 8-12 were
inactive (Figure 3.6 A, Table 3-2). In this assay, Gli1 protein expression was induced
by 12-h treatment with tetracycline. Removal of tetracycline after another 12 h,
followed by the addition of samples eliminated the undesired production of GLI1 via
CMV promoter activation. Cell viability of compounds was checked simultaneously
with luciferase activity under a fluorimetric microculture cytotoxicity assay (FMCA)
system.10 Of the 3 active compounds, compound 6 appeared to be the most potent
Hh/GLI-1 inhibitor.
We further examined the cytotoxicity of active compounds against PANC1, DU145
and C3H10T1/2 using the FMCA system. The results revealed that compounds 6,
7 and 13 were cytotoxic against PANC1 cells (IC50 values of 0.7, 20.0 and 1.8 µM,
respectively) and DU145 cells (IC50 values of 0.8, 22.0 and 2.4 µM, respectively)
but did not affect normal cell lines (Figure 3.6 B, Table 3-2). The cytotoxicity of
6, 7 and 13 against PANC1 and DU145 cells may be associated with their Hh/GLI
transcriptional activity inhibition.
To ensure that the inhibition of Hh signaling by 6 was associated with the expres-
sion of GLI-related proteins (PTCH and BCL-2) and to identify the effect of 6 on
downstream events, we checked the protein levels of full, cytoplasmic and nuclear
25
Figure 3.6: (A) Inhibition of GLI1-mediated transcriptional activity (solid columns)
and cell viability (solid curves) of compounds 6, 7 and 13. HaCaT-GLI1-Luc cells
were seeded onto a 96-well plate (2 x 105 cells per well) and then treated with
compounds 12 h after tetracycline addition. Cell viability and luciferase activity
were determined at the same time. (B) Cytotoxicity of compounds 6, 7 and 13
against PANC1, DU145, and C3H10T1/2 cells. Assays were performed at 0.05 %
DMSO (n=3). Error bars represent s.d.
PANC1 after treatment with 6. As a result, 6 reduced the expression of PTCH and
BCL-2 proteins in a dose-dependent manner. Our Western blot result also showed
that treatment with 6 at a concentration of 1.6 µM led to a significant decrease in
the protein level of nuclear GLI1 in PANC1 (Figure 3.7 A).
To further understand the molecular mechanism underlying the Hh signaling in-
hibitory effect of 6, we checked the expression of a GLI-related gene (Ptch) using
real-time quantitative RT-PCR. It has previously been suggested that Ptch is a
repressive Hh receptor, and elevated expression of this gene results in the concomi-
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tant expression of Hh target genes, including GLI1.11 Consistent with this, our data
showed that the downregulation of Ptch mRNA expression is essential for the inhi-
bition of Hh/GLI1 signaling on PANC1 treated with 6 (Figure 3.7 B).
Loss of Ptch function has been reported to cause aberrant Hh signaling by Smo.12
Most known Hh modulators, including cyclopamine, repress the pathway by antag-
onizing Smo activation; however, one of the oncogenic Smo mutants (SmoM2) is
apparently resistant to cyclopamine13 and most Smo inhibitors were not effective
against medullablastoma and cancer associated with downstream lesions.14
To verify the function of Smo in PANC1 during the Hh inhibition of 6, we knocked
down Smo expression in PANC1 cells by siRNA and performed real-time quantita-
tive RT-PCR on its mRNA expression. Transfection of a non-targeting siRNA at
the same concentration served as a control. The transfection results, as confirmed by
Western blotting, proved the total depletion of the Smo protein level after a silencing
process (Figure 3.7 C, bottom panel). Accordingly, silencing of Smo siRNA signif-
icantly reduced the expression of Ptch mRNA expression in PANC1 cells treated
with 6 (Figure 3.7 C, upper panel). These results thus indicated that 6 inhibited
Hh signaling in an Smo-independent manner.
Because the inhibitory effect of 6 resulted in the decreased level of GLI1-related
proteins (PTCH and BCL-2) as well as blocking GLI1 transcription factor translo-
cation into the nucleus in PANC1 cells (Figure 3.7 A), we may speculate that this
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Figure 3.7: (A) Effect of compound 6 on GLI1 and/or GLI-related protein (PTCH
and BCL2) levels in full, cytosolic and nuclear PANC1 cells. (B) Inhibition of Ptch
mRNA expression by compound 6 in PANC1 cells. GAPDH was used as an internal
control. Assays were performed at 0.05 % DMSO (n = 3). Error bars represent s.d.
(C) Expression of Ptch mRNA (upper panel) and Smo protein (bottom panel) in
PANC1 treated with 6 after siRNA-mediated silencing of Smo.
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compound antagonizes GLI1 activator function. In accordance with this result, sev-
eral reports have previously described that GLI function can be modulated without
Smo interference via numerous types of GLI signaling, such as transforming growth
factor- (TGF),15 mitogen-activated protein kinase (MAPK)16 and posphatidylinos-
itol 3-kinase (PI3K)/Akt signaling.17
In conclusion, we have isolated naturally occurring Hh/GLI inhibitors including 2
new compounds (6-7) from Excoecaria agallocha. Compound 6 inhibited the translo-
cation of GLI1 transcription factor into the nucleus of PANC1. Quantitative RT
PCR of 6 exhibited that the reduction of Hh signaling was not caused by Smo inter-
ference, but rather by other unrevealed mechanisms related to the GLI1 inhibitory
function. This is the first report of an Hh/GLI signaling inhibitor which reduces the
level of GLI1 in the nucleus.
3.4 Acid Hydrolysis
Compounds 6 (4 mg) and 7 (1.5 mg) were respectively reacted in 6 mL and 3 mL
of 5 % H2SO4 for 1 hour at 95
0C. Five drops of water were added and then each
mixture was partitioned with EtOAc three times. The EtOAc layer was washed
with saturated aqueous NaHCO3 and H2O, dried over Na2SO4 and concentrated.
Aglycones of 6 (2 mg) and 7 (0.6 mg) were identical to quercetin by comparing the
NMR data with the literature. The H2O-soluble part of 6 was purified by Amberlite
IRA 96 SB AG (10 x 210 mm; eluent, H2O) to give the sugar part (1.8 mg). Sugar
of 7 was purified by reverse-phase HPLC (CAPCELL PACK 4.6 x 250 mm; eluent
H2O/MeOH=15/85, flow rate 1 mL/min, detection UV at 232 nm) to give D-apiose
(tR 5.0 min, 0.3 mg) and L-acofriose (tR 18.5 min, 0.4 mg).
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Figure 3.8: Structures of Compounds 8-13
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Chapter 4
Separation of Vallaris glabra
Vallaris glabra Kuntz. (apocynaceae) (Figure 4.1) is well known to the natives of
Thailand and locally named as bread flowers. Its phytochemical study revealed
the presence of monoterpenes, sequiterpenes and acyclic monoterpene alcohols.1 No
papers reported about the potential therapeutical use of the plant.
4.1 Extraction and Isolation
The MeOH extract (10.0 g) of dried leaves of Vallaris glabra was partitioned be-
tween hexane, EtOAc, and BuOH. The EtOAc extract (817.1 mg) was subjected to
silica gel PSQ100B column chromatography (30 x 350 mm) and eluted successively
with a hexane-EtOAc solvent system (8:1 to 1:1) to yield 8 fractions (1A to 1H).
Fraction 1H (51 mg) was chromatographed over silica gel PSQ100B (12 x 250 mm),
using a hexane-EtOAc solvent system to afford compound 14 (6.0 mg). Another
active fraction from the EtOAc extract (fraction 1G, 44 mg) underwent ODS flash
chromatography (12 x 245 mm), eluted with increasing MeOH (30-100 %) in H2O
to give compound 15 (1.0 mg).
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Figure 4.1: Vallaris glabra
4.2 Structure Elucidation
One new compound (15) and one known compound (14) were isolated from Vallaris
glabra (Figure 4.2). The structure elucidation of known compound, acoschimper-
oside P, 2’-acetate (14), was on the basis of comparison with spectral data of the
reported values.2
4.2.1 Known Compound
Acoschimperoside P, 2’-acetate (14)
1H and 13C NMR data, see Table 3-4, FAB-MS m/z [M + Na]+ 657
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Figure 4.2: Isolation Scheme of Vallaris glabra
4.2.2 New Compound
Compound 15 (Figure 4.3) was obtained as a pale yellow powder and had a molecular
weight at m/z 657.3353 ([M+Na]+, ∆-1.3 mmu), corresponding to the molecular
formula of C34H50O11 in the HR-FABMS. The IR absorption bands suggested the
presence of hydroxyl (3395 cm−1) (br) and carbonyl (1733 cm−1) groups. The UV
absorption maxima were at UV (MeOH) λ max 216 nm (log  3.8) and 275 nm (log
 2.1). Spectral data of compound 15 showed three ester C=O groups (δC 173.7;
δC 169.8; δC 169.5), olefin (δH 6.31; δC 121.2, 170.3), and an oxygenated CH2 (δH
5.43, 5.27; δC 75.8) (Fig. 1, Table 1). Acid hydrolysis gave D-acofriose, whose D
form was identified by comparison of [α]20D -28.4 (c 0.1, MeOH) with the literature
(-27.0).3 The α configuration of D acofriose was assigned based on the downfield
36
Figure 4.3: Structure of Compound 15, key 1H-1H COSY and HMBC correlations
observed for 15
chemical shift of its anomeric proton (δH 5.11).
4,5 The sugar part was attached to
the O-atom at C-3 of the aglycone on the basis of an HMBC correlation between
the anomeric H-atom and C-3 at the δC 70.2 (Figure 4.3).
4.3 Activity Assay
The Hh/GLI inhibitory effect of compounds 14 and 15 were further evaluated.
Compound 14 inhibited Hh/GLI-mediated transcriptional activity with IC50 value
of 2.3 µM (Figure 4.4, Left), whereas compound 15 was inactive (data is summarized
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in Table 4-1). Compound 14 was cytotoxic against PANC1 cells (IC50 value of 3.6
µM) and DU145 cells (IC50 value of 1.8 µM) but less affect a normal cell line (Figure
4.4, Right). This cytotoxicity effect may be associated with the ability of compound
14 to inhibit Hh/GLI1 signaling pathway. Similar type of cardiac glycosides, isolated
from Adenium obesum, were previously also identified as Hh inhibitors.8
Figure 4.4: (Left) Inhibition of GLI1-mediated transcriptional activity (solid
columns) and cell viability (solid curves) of compounds 14. HaCaT-GLI1-Luc cells
were seeded onto a 96-well plate (2 x 105 cells per well) and then treated with
compounds 12 h after tetracycline addition. Cell viability and luciferase activity
were determined at the same time. (Right) Cytotoxicity of compounds 14 against
PANC1, DU145, and C3H10T1/2 cells. Assays were performed at 0.05 % DMSO
(n=3). Error bars represent s.d.
To ascertain whether the inhibition of Hh signaling by 14 was associated with the
expression of GLI-related proteins (PTCH and BCL-2), protein lysates of PANC1-
treated with 14 was blotted and analyzed. Reduced expression of PTCH and BCL-2
proteins in a concentration-dependent fashion, as confirmed by western blot anal-
ysis, suggesting that the block of Hh signaling inhibited the expression of tumor
suppressor and antiapoptosis proteins (Figure 4.5).
In conclusion, two cardiac glycosides were isolated from the leaves of Vallaris glabra.
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Figure 4.5: Inhibition of GLI-related protein (PTCH and BCL2) levels by compound
14 in PANC1 cells.
Compound 14 but not 15 was active in the assay for Hh signaling inhibition. In
further experiments, compound 14 showed a strong cytotoxicity against human
pancreatic (PANC1) and human prostate (DU145) cancer cells. The expression of
GLI-related proteins (PTCH and BCL-2) according to a dose-dependent manner
were also inhibited by 14.
4.4 Acid Hydrolysis
Compound 15 (1.0 mg) in 5 % aq.HCl (1.5 mL) was heated at 95 oC for 1 hour.
After cooling to room temperature, H2O was added then extracted with EtOAc (x
3). The aqueous layer was neutralized with 10 % aqueous Na2CO3 solution (2 mL).
Aglycone of 15 (0.5 mg) was identical to aglycone of acovenoside B by comparing
the NMR data with the literature.6 Sugar part of 15 (D-acofriose, 0.4 mg) was
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identified based on RF and αD values of references.
3,7 Thin-layer chromatography
(TLC) was performed on aluminium sheets coated with kieselgel (silica gel, type 60
F254, Merck), RF = 0.72 (EtOAc/MeOH, 2:1). [α]
20
D -28.4 (c 0.1, MeOH) (lit.-27.0).
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Figure 4.6: Structures of Compounds 14-15
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Chapter 5
Separation of Ocimum
gratissimum
Ocimum gratissimum L (Lamiaceae) (Figure 5.1) commonly known as alfavaca is
naturally used in treatment of different diseases, for example upper respiratory infec-
tions, diarrhea, headache, fever, ophtalmic, skin disease.1 Volatile oil and chromenes
have been isolated from this species, and have been reported to have anthelmintic
effect.2
5.1 Extraction and Isolation
The chlorophyll free fraction (9.81 g) of extract, suspended in 10 % aq. MeOH, was
partitioned x 3 with hexane, EtOAc and BuOH sucessively to give 1.82 g hexane
extract. This active extract was separated by chromatography on silica gel 60 N (50
x 280 mm) with increasing amounts of EtOA in Hexane as eluent to afford fraction
2A-2E. Fraction 2B and 2C were pure compounds and have identified as compound
16 (5.74 mg) and 17 (25.9 mg). Fraction 2A (981 mg) was further underwent ODS
open column chromatography (50 x 250 mm) to give fraction 3A-3K. Separation of
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Figure 5.1: Ocimum gratissimum
fraction 3D (18.2 mg) on silica gel column chromatography yielded compounds 18
(8.2 mg), 19 (5.4 mg), and 20 (3.1 mg). Fraction 3F (51.6 mg) was subjected to
preparative HPLC [Capcell Pack C.18 type Acr, 6 x 250 mm; MeOH : H2O (3 :1);
flow rate: 1.7 mL/min; RI and UV detection at 254 nm] to obtain compound 21
(2.1 mg). Fraction 4D (19.1 mg), afforded from the separation of fraction 3E (130.5
mg), was subjected to ODS open column chromatography (30 x 180 mm) to give
compound 22 (2.2 mg), 23 (6.2 mg), 24 (1.2 mg), 25 (0.8 mg), 26 (2.0 mg), 27 (1.5
mg), and 28 (5.0 mg) (Figure 5.2).
5.2 Structure Elucidation
Three type of compounds were isolated fromOcimum gratissimum including chromenes
which were commonly isolated. Triterpenes and flavones, however, were the first iso-
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Figure 5.2: Isolation Scheme of Ocimum gratissimum
lated from this flowering type plant. Isolated compounds (16-28) were identified by
comparing their spectroscopic data to literature values.
2β,19α -Glutin-7,21-diene-2,19-diol (16)3
1H and 13C NMR data, see Table 5-1, ESIMS m/z [M + Na]+ 477
Friedoolean-8-en-3-ol-8, 29-diene (17)4
1H and 13C NMR data, see Table 5-1, ESIMS m/z [2M + Na]+ 899
6-(1-methoxyethyl)-5,7-dimethoxy-2,2-dimethylchromene (18)5
1H and 13C NMR data, see Table 5-2, ESIMS m/z [M + Na]+ 301
6-(1-methoxyethyl)-7-methoxy-2,2-dimethylchromene (19)6
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1H and 13C NMR data, see Table 5-2, ESIMS m/z [2M + Na]+ 519
6-(1-hydroxyethyl)-7-methoxy-2,2-dimethylchromene (20)6
1H and 13C NMR data, see Table 5-2, ESIMS m/z [M + Na]+ 257
Evodione (21)5
1H and 13C NMR data, see Table 5-2, EIMS m/z [M + Na]+ 285
Precocene (22)7
1H and 13C NMR data, see Table 5-2, EIMS m/z [M + Na]+ 243
5,7,2’-trimethoxy-3’,4’-methylendioxyflavone (23)8
1H and 13C NMR data, see Table 5-3, FAB-MS m/z [M + H]+ 357
5,6,7,8,3’,4’,5’-heptamethoxy-flavone (24)9
1H and 13C NMR data, see Table 5-3, ESIMS m/z [M + Na]+ 455
5,6,7,3’,4’,5’-hexamethoxy-flavone (25)8
1H and 13C NMR data, see Table 5-3, ESIMS m/z [M + Na]+ 425
5,6,7,2’-tetramethoxy-3’,4’-methylendioxyflavone (26)8
1H and 13C NMR data, see Table 5-3, FAB-MS m/z [M + H]+ 387
Eupalestin (27)9
1H and 13C NMR data, see Table 5-3, ESIMS m/z [M + Na]+ 439
f
¯
5,6,2’,5’,6’-pentamethoxy-3’,4’-methylendioxyflavone (28)10
1H and 13C NMR data, see Table 5-3, FAB-MS m/z [M + H]+ 417
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5.3 Activity Assay
The isolated compounds (16-28) were tested in the inhibition of GLI-mediated
transcriptional activity and data is summarized in Table 5-4. Compound 18 showed
moderate inhibition of GLI-mediated transcriptional activity, evidenced by the IC50
value of 10.0 µM (Figure 5.3, Left, Table 5-4). This compound was cytotoxic against
cancer cells (PANC1 and DU145), in which Hh signaling is aberrantly activated
(Figure 5.3, Right, Table 5-4). This result was in agreement with a significant
reduction of the expression of anti-apoptosis BCL-2 and tumor suppressor PTCH in
PANC1 after the treatment of 18 in a concentration-dependent manner (Figur 5.4).
Figure 5.3: (Left) Inhibition of GLI1-mediated transcriptional activity (solid
columns) and cell viability (solid curves) of compounds 18. HaCaT-GLI1-Luc cells
were seeded onto a 96-well plate (2 x 105 cells per well) and then treated with
compounds 12 h after tetracycline addition. Cell viability and luciferase activity
were determined at the same time. (Right) Cytotoxicity of compounds 18 against
PANC1, DU145, and C3H10T1/2 cells. Assays were performed at 0.05 % DMSO
(n=3). Error bars represent s.d.
In conclusion, chromatographic separation of the leaves of Ocimum gratissimum
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afforded 13 known compounds. An attempt was made to examine the Hedgehog/GLI
inhibition of all isolated compounds; however, only compound 18 showed moderate
inhibition. The Hh/GLI signaling inhibition may be associated with the significant
decrease of BCL-2 and PTCH protein level in PANC1.
Figure 5.4: Inhibition of GLI-related protein (PTCH and BCL2) levels by compound
18 in PANC1 cells.
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Figure 5.5: Structures of Compounds 16-28
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Chapter 6
Separation of Piper chaba
Piper chaba (Piperaceae) (Figure 6.1) is a climbing glabrous creeper, cultivated
in various parts of Asia, including in Bangladesh. Roots and fruits of this plant
are particularly useful in asthma, bronchitis, and abdomen pain.1 Several alkaloids
containing piperidine moiety have been isolated from Piper species.2 Lignan types
were also isolated from this plant.1
6.1 Extraction and Isolation
MeOH extract of Piper chaba leaves (3.53 g) chromatographed over Diaion HP-20
to remove chlorophyll. The MeOH soluble extract (2.18 g) was then partitioned
between hexane, EtOAc and BuOH. The EtOAc extract was underwent ODS open
column chromatography (50 x 280 mm) to give 14 fractions. Fraction 3D (14.0 mg)
was subjected to preparative HPLC [Capcell Pack C.18 type Acr, 4.6 x 250 mm;
MeOH : H2O (3 : 2); flow rate: 2.0 mL/min; RI and UV detection at 254 nm] to
obtain compounds 29 (3.2 mg), 30 (1.5 mg), 31 (2.0 mg), 32 (1.7 mg), 33 (1.9 mg),
and 34 (2.2 mg). Another active fraction (2G, 11.2 mg) was subjected to Sephadex
LH-20 (12 x 180 mm) to get fraction 4A-4E. As fraction 4C (3.0 mg) and fraction 4D
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Figure 6.1: Piper chaba
(3.4 mg) showed similar TLC spots, these 2 fractions were combined and subjected
to preparative HPLC [Capcell Pack C.18 type Acr, 4.6 x 250 mm; MeOH : H2O (3
:1); flow rate: 1.5 mL/min; RI and UV detection at 254 nm] to afford compounds
35 (0.8 mg), 36 (1.2 mg), 37 (0.7 mg), 38 (2.6 mg), and 39 (0.6 mg). Meanwhile,
compound 40 (6.0 mg) was obtained from the separation of the active fraction 2F
(8.0 mg) under preparative HPLC [Inertsil ODS-3, 10 x 250 mm; MeOH : H2O (1
:1); flow rate: 1.5 mL/min; RI and UV detection at 254 nm].
6.2 Structure Elucidation
The continued chromatography of the EtOAc soluble fraction of Piper chaba, guided
by Hh/GLI signaling inhibition, afforded 11 known compounds (29-39) and 1 new
compound (40) (Figure 6.2). The basic skeleton of 29-40 were determined to be
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Figure 6.2: Isolation Scheme of Piper chaba
lignan types by virtue of a common set of 1H NMR spectra that displayed 1, 3, 4
tri-substituted phenyl system possessing methylendioxy and methoxyl groups in two
different ring systems.
6.2.1 Known Compounds
Kusunokinin (29)3
1H and 13C NMR data, see Table 6-3, ESIMS m/z [M + Na]+ 393
3-(3,4-dimethoxy-benzyl)-4-(7-methoxy-benzo [1.3] dioxol-5-yl-methyl)-
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dihydrofuran-2-one (30)4
1H and 13C NMR data, see Table 6-3, ESIMS m/z [M + Na]+ 423
Burseran (31)5
1H and 13C NMR data, see Table 6-3, ESIMS m/z [M + Na]+ 409
Haplomyrfolol (32)6
1H and 13C NMR data, see Table 6-4, ESIMS m/z [M + Na]+ 381
5β-hydroxy-3”,4”-dimethoxy-2-5-epoxy lignan (33)7
1H and 13C NMR data, see Table 6-4, ESIMS m/z [M + Na]+ 395
5α-hydroxy-3”,4”-dimethoxy-2-5-epoxy lignan (34)7
1H and 13C NMR data, see Table 6-4, ESIMS m/z [M + Na]+ 395
Dihydroclusin (35)8
1H and 13C NMR data, see Table 6-5, FAB MS m/z [M + Na]+ 427
3R,4R,5S-cubebin (5β-cubebin) (36)9
1H and 13C NMR data, see Table 6-5, FAB MS m/z [M + Na]+ 379 [α]21D -105.0 (c
0.12, CHCl3)
3R,4R,5R-cubebin (5α-cubebin) (37)9
1H and 13C NMR data, see Table 6-5, FAB MS m/z [M + Na]+ 379 [α]21D -50.4 (c
0.07, CHCl3)
Saururenin (38)10
1H and 13C NMR data, see Table 6-5, FAB MS m/z [M + Na]+ 365
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Saururin (39)10
1H and 13C NMR data, see Table 6-5 FAB MS m/z [M + Na]+ 379
Figure 6.3: Structure of Compound 40
6.2.2 New Compound
Compound 40 (Figure 6.3) was isolated as a white amorphous solid and gave the
molecular formula C21H24O6, as deduced from HR-FABMS m/z 395.1294 (calcd for
C21H24O6Na, 395.1305). The IR absorption bands suggested the presence of hy-
droxyl (3490 cm−1) (br) and aromatic (1620, 1450 cm−1) groups and methylendioxy
(935 cm−1). The UV absorption maxima were at UV (MeOH) λ max 282 nm (log
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Figure 6.4: Key 1H-1H COSY, HMBC, and NOE correlations observed for 40
 3.1) and 230 nm (log  3.0). The 1H NMR spectrum gave a characteristic signal
for the methylenedioxy function at δ 5.93. Appearance of two singlets at δH 3.93
and 3.78 confirmed the presence of 2 methoxyl groups. The position of these groups
were confirmed by the HMBC correlation. One methoxy (δH 3.93) attached to C-3’
(δC 149.0) of the benzene ring whereas another (δH 3.78) was attached to C-6 (δC
89.8) (Figure 6.4).
Although analysis of IR confirmed the presence of a hydroxyl group (3490 cm−1, br),
the position of -OH was difficult to assign because of the absence of HMBC signals.
From NOE effects, it was found that hydroxyl protons (δ 5.57) was correlated to
methoxyl proton (δ 3.78). Therefore, this data suggested that the hydroxyl group
was attached at C-4’.
The stereochemistry at the chiral centres (3, 4) of 40 was assigned on the basis of
both coupling constant data and NOE correlations (Figure 6.4). 1D-NOE experi-
ments showed interaction between H-4 and H-3 as well as H-5. An NOE correlation
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was also observed between H-3 and H-2, which confirmed that both H-3 and H-4 were
cis-oriented. These data suggested that the relative configuration (3S*, 4R*) of the
chiral centres in five-membered ring of 40 was similar to that of the aforementioned
compound isolated by Pu, Jian-Xin, et al in 2007.11
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Figure 6.5: (A) Inhibition of GLI1-mediated transcriptional activity (solid columns)
and cell viability (solid curves) of compounds 31 and 40. HaCaT-GLI1-Luc cells
were seeded onto a 96-well plate (2 x 105 cells per well) and then treated with
compounds 12 h after tetracycline addition. Cell viability and luciferase activity
were determined at the same time. (B) Cytotoxicity of compounds 31 and 40
against PANC1, DU145, and C3H10T1/2 cells. Assays were performed at 0.05 %
DMSO (n=3). Error bars represent s.d.
6.3 Activity Assay
Hh/GLI1 inhibitory effects and cytotoxicity against cancer cells of all isolated com-
pounds (29-39) were further examined. The data of IC50 values was summarized in
Table 6-2. Among isolated compounds, 31 and 40 were apparently to be the most
potent inhibitors of Hh/GLI-mediated transcriptional activity, approved by their
IC50 values at 6.8 and 4.1 µM respectively (Figure 6.5 A, Table 6-2).
The cytotoxicity of active compounds against PANC1, DU145 and C3H10T1/2 using
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Figure 6.6: Inhibition of GLI-related protein (PTCH and BCL2) levels by compound
31 and 40 in PANC1 cells.
the FMCA system was further checked. The results revealed that compounds 31 and
40 were cytotoxic against PANC1 cells (IC50 values of 5.5 and 4.0 µM, respectively)
and DU145 cells (IC50 values of 4.7 and 5.3 µM, respectively) but less affect normal
cell lines (Figure 6.5 B, Table 6-2). The Western blot result further confirmed that
treatment of 31 and 40 at a concentration-dependent manner led to a significant
decrease in the protein level of PTCH and BCL-2 in PANC1 (Figure 6.6).
In conclusion, twelve lignan type compounds were obtained from the separation of
Piper chaba leaves guided by Hh/GLI signaling inhibition. Compounds 31 and 40
showed strong inhibition of Hh/GLI and selected cytotoxicity against cancer cells
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(PANC1, DU145). In accordance with this result, Western blot analysis confirmed
that compound 31 and 40 significantly reduced the expression of tumor supressor
PTCH and anti apoptosis BCL-2 in PANC1 in a dose-dependent manner.
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Figure 6.7: Structures of Compounds 29-39
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Chapter 7
Experimental
7.1 General
Optical rotation : JASCO P-1020 polarimeter
UV spectra : Shimazu UV mini-1240 spectrometer
CD spectra : JASCO J-720W1 spectrometer
IR spectra (ATR) : JASCO FT-IR 230 spectrometer
NMR spectra : JEOL A 400, JEOL A 500, ECP 400, ECP 600 spectrometers
(deuterated solvents, the chemical shift
of which was used as an internal standard)
FABMS : JEOL JMS-AX500 spectrometer
HRFABMS : JEOL HX-110A spectrometer
HREIMS : JEOL JMS-AX500 spectrometer
HRESIMS : Thermo scientific exative
Incubator : CO2 MCO-17A1, SANYO 37
0C 5% CO2
Clean beanch : Bio Clean Bench MCV-B131S, SANYO
RT PCR : Termal Cycler Dice (TaKaRa)
Mx3000P QPCR system (Stratagene)
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Cell Culture
HaCaT Human keratinocyte-GLI1
HaCaT-GLI1 (gifted by Dr. Fritz Aberger and Gerhard Regl)
Dulbecco’s modified Eagle Medium (DMEM, high glucose, Wako) + 5% fetal bovine
serum (FBS, biowest)
HaCaT-GLI1-luc
DMEM (high glucose, Wako) + 5 % FBS and Penicillin (200 unit/mL) or Strepto-
mycin (200 mg/mL) (Gibco)
PANC1 (human pancreatic cancer cell, provided by RIKEN BRC)
RPMI-1640 (Wako) + 10 % FBS
DU145 (human prostate cancer cell, provided from Cell Resource Center for Biomed-
ical Research Institute of Development, Aging and Cancer Tohoku University)
RPMI-1640 (Wako) + 10%FBS
C3H10T1/2 (mouse embryonic fibroblast cell, provided by RIKEN BRC)
DMEM (high glucose, Wako) + 10 % FBS
Fetal Bovine Serumn (FBS, Biowest), Trypsin EDTA (0.25% Trypsin-EDTA, Gibco)Trypan
blue (0.4%(w/v) trypan blue, Nacalai tesque Inc.), Penicillin (10,000 unit/mL)
Streptomycin (10,000 g/mL) (Gibco), Blasticidin S Hcl (Invitrogen), Zocin (Invit-
rogen), Puromycin (SIGMA), Tetracycline (Invitrogen).
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PBS :
KCl (Nacalai tsque Inc.) 0.2 g
KH2PO4 (Nacalai tesque Inc.) 0.2 g
NaCl (Nacalai tesque Inc.) 8.0 g
Na2HPO4 (Nacalai tesque Inc.) 1.11 g
dH2O up to 1 L (autoclaved; 121
0C, 20 min)
SDS-PAGE
Running gel Stacking gel
Material 12.5% 10 % 7.5 % 5 %
H2O 2.2 mL 3.1 mL 3.9 mL 3.4 mL
30 % acrylamide 4.2 mL 3.3 mL 2.5 mL 0.83 mL
1 M Tris-HCl (pH 8.8) 3.4 mL 3.4 mL 3.4 mL —
1 M Tris-HCl (pH 6.8) — — — 0.63 mL
10 % SDS 0.1 mL 0.1 mL 0.1 mL 0.05 mL
10 % ammonium persulfate 0.1 mL 0.1 mL 0.1 mL 0.05 mL
TEMED 7 µL 7 µL 7 µL 3 µL
10 x Running Buffer:
Tris 30.3 g (0.25 M)
glycin 144 g (1.92 M)
SDS 10 g (1 % (w/v))
dH2O up to 1 L
5 x SDS Buffer:
0.5 M Tris-HCl (pH 6.8) 15.7 mL (0.313 M)
SDS 2.5 g (10 % (w/v))
sucrose 6.25 g (25 %(w/v))
bromo phenol blue 6.25 mg (0.025 % (w/v))
dH2O up to 25 mL
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TBST (Tris-Buffered Saline Tween 20):
Tris 3.6 g
NaCl 17.4 g
conc.HCl 2.4 mL
Tween 20 3.0 g
dH2O up to 3 L
Lysis Buffer:
1 M Tris-HCl 2 mL (20 mM)
NaCl 878 mg (150 mM)
Triton X-100 0.5 mL (0.5% (w/v))
sodium deoxycholate 500 mg (0.5 % (w/v))
EDTA 292.2 mg (10 mM)
sodium orthovanadate (Na3VO4) 18.4 mg (1 mM)
sodium fluoride (NaF) 0.42 mg (0.1 mM)
protease inhibitor cocktail 1 mL (1 %(v/v))
dH2O up to 100 mL
30 % Acrylamide:
Acrylamide 29.2 g
N, N’-methylene-bis-acrylamide 0.8 g
dH2O up to 100 mL
7.2 Plant Material
7.2.1 Medicinal Plants Collected from Thailand
The leaves of Acacia pennata and Vallaris glabra were collected in Thailand and
they were sent to Japan on 26th February 2008. Plants were identified by Dr.
Thaworn Kowithayakorn, and voucher specimens (KKP0023 and KKP0252) have
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been deposited in both Khon Kaen University (Thailand) and the Graduate School
of Pharmaceutical Sciences, Chiba University (Japan).
7.2.2 Medicinal Plants Collected from Bangladesh
The leaves of Excoecaria agallocha, Ocimum gratissimum, and Piper chaba were
collected in Bangladesh in November 2008. Plants were taxonomically identified
by Prof. A. K. Fazlul Huq, Forestry and Wood Technology Discipline, Khulna
University, Bangladesh, and voucher specimens (KKB034, KKB054, and KKB108)
have been deposited there for future reference.
7.3 Western Blotting
7.3.1 Isolation of Cellular Extracts
PANC1 cells were seeded into 10 cm dishes (2 x 106 cells) and incubated for 24 h
at 370C. Compounds at various concentrations were added. After 24 h incubation,
cells were washed with PBS and then collected by scraping the whole parts. Protein
lysate was prepared with lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5
% sodium deoxycholate, 10 mM EDTA, 1 mM sodium orthovanadate, and 0.1 mM
NaF) containing a 1 % proteasome inhibitor cocktail (Nacalai Tesque, Japan), and
then centrifuged at 13000 rpm, 40C for 30 min.
7.3.2 Isolation of Cytosolic and Nuclear Proteins
PANC1 cells were seeded into 60 mm dishes (2 x 106 cells), and incubated for 24 h at
370C, after which cells were harvested with trypsin and centrifuged at 1000 rpm at
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40C for 5 min. Protein lysates were prepared in the same way as the isolation of the
whole cellular extract. Nuclear and cytosolic extracts were prepared using NE-PER
nuclear and cytosolic extraction reagents (Pierce) according to the manufacturer’s
instructions.
7.3.3 Western Blotting Procedure
HaCaT-expressed exogenous GLI1 cells were seeded onto a 10 cm dish (2 x 106 cells/
dish), and incubated for 12 h at 370C. To activate expression of exogenous GLI1
protein, 1 g/mL of tetracycline was added into each well, followed by another 12 h
incubation. DMEM medium (containing 5% FBS) was removed and compounds at
various concentrations were added.
After 24 h incubation, cells were washed with PBS then homogenized in lysis buffer
(20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 10 mM EDTA,
1 mM sodium orthovanadate, and 0.1 mM NaF) containing 1% proteasome in-
hibitor cocktail (Nacalai Tesque, Tokyo, Japan), and incubated on ice for 30 min.
Supernatants of the cell lysates, as obtained from a 40C centrifugation (30 min),
were subjected to a 5% and 12.5% SDS-PAGE electrophoresis then transferred to a
polyvinylidine difluoride (PVDF) membrane (Bio-Rad).
Blots were blocked with TBST (10 mM Tris-HCl pH 7.4, 100 mM NaCl and 0.1%
Tween 20) containing 5% skimmed milk for 1 h and hybridized at room temperature
for 1 h with primary antibodies: GLI1, PTCH (Santa Cruz) and BCL-2 (Sigma).
Another 1 hr incubation of blots-hybridized secondary antibodies was performed
at room temperature. The secondary antibodies used were anti-goat IgG (Sigma),
anti-rabbit IgG, and anti-mouse IgG (Amersham Biosciences). After washing with
TBST, immunocomplexed bands were detected using an ECL Advance Western (GE
Healthcare Biosciences) or an Immobilon Western (Millipore) detection system.
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To confirm protein expression level of PTCH and BCL-2 in PANC1, the same
method as described above was performed. PANC1 cells were seeded onto a 6 cm
dish (1 x 106 cells/ dish), and incubated for 12 h at 370C. Compounds, dissolved in
DMSO, replaced RPMI-1640 medium (containing 10 % FBS) after 24-h incubation.
Homogenization and addition of lysis buffer were performed after 24 h to obtain
whole protein lysates. Furthermore, protein lysates of the whole extract, cytosol or
nucleus were blotted and blocked using similar procedures.
To detect GLI1 (150 kDa), PTCH (140 kDa) and BCL-2 (26 kDa), anti-GLI1 (Santa
Cruz Biotechnology), anti PTCH (Santa Cruz Biotechnology), and anti BCL-2
(Sigma) were used as specific primary antibodies followed by anti-goat IgG (Sigma),
anti-rabbit IgG, and anti-mouse IgG (Amersham Biosciences) as the second anti-
bodies. β-actin (45 kDa) was used as an internal control.
7.4 RNA Interference Experiments
PANC1 cells were seeded into 6 cm dishes (4 x 105 cells) and incubated for 12
h. RPMI-1640 medium (containing 10 % FBS) was removed and compounds at
different concentration were added. After 12 h incubation, cells were transfected
with small interfering RNA (20 nM) (SMO siRNAs, Santa Cruz Biotechnology) using
SiPORTTM NeoFXTM (Ambion) and OPTI-MEM (Invitrogen), as described by
the manufacturer. Transfection of a non-targeting siRNA at the same concentration
served as a control (the compound was replaced by DMSO).
To confirm the transfection efficiency of RNA interference, Western blotting was per-
formed prior to quantitative RT-PCR. Anti Smo (Santa Cruz Biotechnology) and
anti-rabbit IgG (Jackson ImmunoResearch Lab. Inc.) were used as first and sec-
ondary antibodies, respectively, followed by enhanced chemiluminescence detection
(GE Healthcare Biosciences).
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7.5 Real Time Polymerase Chain Reaction
7.5.1 Reaction Condition
Reverse transcription:
Incubation 250C 10 min
Reverse transcription reaction 420C 50 min
Deactivation of enzyme 950C 15 sec
RNA degradation:
RNA degradation 370C 20 min
Primers:
GLI1; forward 5’-GCCGTGTAAAGCTCCAGTGAACACA-3’
reverse 5’-TCCCACTTTGAGAGGCCCATAGCAAG-3’ (200 bp product)
Ptch; forward 5’-TCCTCGTGTGCGCTGTCTTCCTTC-3’
reverse 5’-CGTCAGAAAGGCCAAAGCAACGTGA-3’ (200 bp product)
Bcl2; forward 5’-TGGACAACCATGACCTTGGACAATCA-3’
reverse 5’-TCCATCCTCCACCAGTGTTCCCATC-3’
Gapdh; forward 5’-ATGGGGAAGGTGAAGGTCG-3’
reverse 5’-TAAAAGCAGCCCTGGTGACC-3’
PCR condition:
Initial incubation 500C 2 min
Initial denaturation 950C 2 min
Denaturation 950C 15 sec. 40 cycles
Annealing, extension 600C 30 sec.
Dissociation curve analysis 600C 30 sec. 950C 30 sec.
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7.5.2 RT-PCR Procedure
Total RNA was extracted using an Rneasy Mini kit (Qiagen), and cDNA was syn-
thesized using the RT-PCR SuperScript III Platinum Two Step qRT-PCR Kit (In-
vitrogen). The mRNA levels of Ptch were measured on a Mx3000P QPCR system
(Stratagene) at the following annealing temperatures: 500C for 2 min (initial incu-
bation), 950C for 2 min (initial denaturation), and then 40 cycles of 950C for 15 s
(denaturation) and 600C for 30 s (annealing, extension). Each amplification reaction
was performed in triplicate. mRNA quantification is expressed in arbitrary units
and was normalized to an internal control GAPDH.
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Appendix I
Screening of Bangladesh Plant Extracts
KKB001-KKB035
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KKB035-KKB056
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KKB101-KKB117
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Appendix II
List of Bangladesh Plant Extracts
KKB001 Adiantum philipense (Leaves)
KKB002 Asparagus racemosus (Roots)
KKB003 Centella asiatica (Whole plant)
KKB004 Commelina benghalensis (Roots)
KKB005 Flemingia congesta (Leaves)
KKB006 Hygrophila spinosa (Seed)
KKB007 Mesua ferrea / M. nagassarium (Flower)
KKB008 Ocimum sanctum (Whole plant)
KKB009 Sida acuta (Whole plant)
KKB010 Sida rhombifolio (Whole plant)
KKB011 Vitex negundo (Leaves)
KKB012 Derris indica (Leaves)
KKB013 Derris trifoliata (Aerial part)
KKB014 Physalis minima
KKB015 Excoecaria indica (Leaves)
KKB016 Terminalia bellerica
KKB017 Ficus racemosus (Fruits)
KKB018 Ipomoea maxina
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KKB019 Cleoma rutidosperma
KKB020 Cricus arvensis
KKB021 Acacia spp.
KKB022 Heritiera fomes (Leaves)
KKB023 Xylocarpus granatum (Leaves)
KKB024 Hibiscus tiliaceus (Leaves)
KKB025 Ceriops decandra (Leaves)
KKB026 Rhizopora spp. (Leaves)
KKB027 Sonneratia caseolaris (Leaves)
KKB028 Veronia spp. (Stem)
KKB0029 Lumnitzera racemosus (Leaves)
KKB0030 Acanthus ilicifolius (Aerial part)
KKB0031 Crataeva nurvala (Aerial part)
KKB0032 Clerodendrum inerme (Leaves)
KKB0033 Cerbera manghas (Leaves)
KKB0034 Exocoecaria agallocha (Leaves)
KKB0035 Avicennia marina (Leaves)
KKB0036 Ocimum gratissimum (Aerial part)
KKB0037 Thevetia peruviana (Aerial part)
KKB0038 Rhizophoria epiculata (Leaves)
KKB0039 Amoora cucullata (Leaves)
KKB0040 Rhizophora mucronata (Leaves)
KKB0041 Derris trifoliate (Aerial part)
KKB0042 Rhizophora mucronata (Leaves)
KKB0043 Acrostichum aurium (Aerial part)
KKB0044 Cocculus villosus (Leaves with small stem)
KKB0045 Kandelia candela (Leaves)
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KKB0046 Aegiceras corniculatum (Leaves)
KKB0047 Renhydra sp. (Aerial part)
KKB0048 Curcuma zedoaria (Aerial part)
KKB0049 Mallotus spp. (Leaves with small stem)
KKB0050 Urginea indica (Aerial part)
KKB0051 Alombus spp. (Aerial part)
KKB0052 Pongamia pinnata (Leaves)
KKB0053 Pongamia pinnata (Fruits)
KKB0054 Ocimum gratissimum (Leaves)
KKB0055 Cyperus spp. (Whole plant)
KKB0056 Pandanus foetidus (Aerial part)
KKB0101 Murraya koenigii (Leaves)
KKB0102 Swietenia mahagoni (Leaves)
KKB0103 Aegle marmelos (Leaves)
KKB0104 Seseli diffusum (Seeds)
KKB0105 Alostonia scholaris (Stem Barks)
KKB0106 Vallaris solanacea (Leaves)
KKB0107 Vallaris solanacea (Stem)
KKB0108 Piper chaba (Leaves)
KKB0109 Piper chaba (Roots)
KKB0110 Primna integrifolia (Leaves and stems)
KKB0111 Phyllanthus emblica (Fruits)
KKB0112 Terminalia bellirica (Fruits)
KKB0113 Terminalia chebula (Fruits)
KKB0114 Boerhavia diffusa (Leaves and stems)
KKB0115 Ruellia tuberosa (Stem)
KKB0116 Saussurea hypoleucav (Roots)
KKB0117 Solanum indicum (Leaves and stems)
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Appendix III
Characteristics of New Compounds
Compound 6: Yellow powder, [α]20D -140 (c 0.1, MeOH), UV(MeOH) λ max (log )
261 nm (3.8); 355 nm (3.0); IR (ATR) max 3317 (br), 2948, 2835, 1652, 1449, 1417,
1015 cm−1; HR-FABMS m/z 485.1162 [M+Na]+ (calcd for C22H24O11Na, 485.1173)
; 1H NMR and 13C NMR (DMSO-d6 ) (Table 3-1).
Compound 7: Yellow amorphous solid, [α]20D -152 (c 0.3, MeOH), UV(MeOH) λ
max (log ) 259 nm (3.1); 362 nm (2.5); IR (ATR) max 3333 (br), 2944, 2832, 1655,
1449, 1364, 1117 cm−1 ; HRESIMS m/z 617.1584 [M+Na]+ (calcd for C27H30O15Na,
617.1558) ; 1H NMR and 13C NMR (DMSO-d6) (Table 3-1).
Compound 14: Pale yellow powder; [α]20D -32 (c 0.11, MeOH); UV (MeOH) λ max
(log ) 216 nm (3.8) and 275 nm (2.1); IR (ATR) max 3395 (br), 2922, 1733,
1568, and 1447 cm−1; HR-FABMS m/z 657.3353 [M+Na]+ (calcd for C34H50O11Na,
657.3366); 1H NMR and 13C NMR (Pyridine-d5) (Table 4-2).
Compound 40: White amorphous solid; [α]20D +57.7 (c 0.6, MeOH); UV (MeOH) λ
max (log ) 230 nm (3.0) and 282 nm (3.1); IR (ATR) max 3490 (br), 1620, 1502,
1450, and 935 cm−1; HR-FABMS m/z 395.1294 [M+Na]+ (calcd for C21H24O6Na,
395.1305); 1H NMR and 13C NMR (CDCl3) (Table 6-1).
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1H NMR and 13C NMR (in DMSO-d6) of compound 6
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1H NMR and 13C NMR (in DMSO-d6) of compound 7
84
1H NMR and 13C NMR (in Pyridine-d5) of compound 14
85
1H NMR and 13C NMR (in CDCl3) of compound 40
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